Fig. 7From: A drug screening to identify novel combinatorial strategies for boosting cancer immunotherapy efficacyFlow cytometry assays to analyze the tumor immune microenvironment in PD1 combined with JK184 treated MC38 tumors. Representative images of A tumor-infiltrating lymphocytes, B CD3+ T cells, C CD8+ T cells, D granzyme B+ T cells, E IFN-γ+ T cells, F CD4+ FOXP3+ T cells, and G myeloid-derived suppressor cells (MDSCs). The relative quantitative analysis was performed by the ratio of tumor-infiltrating immune cells to total alive cells in the prepared cell suspension. T tests were used to determine statistical significance of the differences as indicated: *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001, ns not significantBack to article page